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INTRODUCTION 
The mitral valve connects the left atrium to the left ventricle and consists of the annulus with its two 
leaflets. The average annulus cross-sectional area ranges from 5 to 11.4 cm2 in a normal human 
heart. Both mitral leaflets are connected to chorda tendinea that again connect to the papillary 
muscles in the left ventricle. A sufficient valve prevents systolic leakage of blood to the atrium, and 
the papillary muscles contribute to apical movement of the annulus during systole, thus enhancing 
emptying of the left ventricle. 
 
The term cardiomyopathy is used to describe heart disease resulting from a primary abnormality in 
the myocardium. Although the term ischemic cardiomyopathy has gained popularity among 
clinicians to describe chronic heart failure caused by coronary heart disease1, the pathological 
diagnosis should be chronic ischemic heart disease. 
 
In most instances, there has been a prior myocardial infarct, an unstable coronary syndrome or 
angina pectoris, and often these patients will show symptoms of generalized atherosclerotic disease. 
The non-infarcted viable myocardium usually undergoes both compensatory hypertrophy and 
dilatation. Wall tension increases, fibrosis follows and diastolic and systolic dysfunction develop. 
The patients then develops mitral regurgitation2, first during ischemia; later the valve leakage 
becomes permanent. One effect of mitral regurgitation is reduced systemic blood flow (forward 
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failure). The backward mitral flow increases left atrial pressure, and the atrium dilates. Atrial wall 
stretch increases, predisposing to atrial fibrillation which adds further to the decompensation of the 
left side of the heart. Pressure and volume overload in the atrium leads to dilatation and 
hypertrophy, the contribution of each may vary. In the ventricle, remodelling is mainly expressed as 
dilatation, due to volume overload. The end-stage of this development is heart failure, and in 
advanced cases, pulmonary congestion and even of right sided heart failure (hepatomegali and 
peripheral edemas are severe signs). 
 
The clinical symptoms and signs of mitral regurgitation is a systolic heart murmur with an apical or 
axillar point of maximum, weakness, fatigue, palpitations and dyspnoea. The patients are at 
increased risk for contracting bacterial endocarditis. The degree of heart failure is described by the 
New York Heart Association (NYHA)-classes I-IV. 
 
In our study we followed a group of patients with severe ischemic cardiomyopathy with EF<25%, 
who underwent mitral valve repair. The natural history of these patients is very bad. Mortality has 
been reported to 31% within one year3. Those with congestive heart failure and mitral regurgitation 
have a life expectancy of less than 12 months4. Following acute MI, approximately 20% develop 
ischemic mitral regurgitation5.  
 
Mitral valve repair is beneficial for this group of patients and is, whenever possible, the treatment of 
choice. Mitral valve replacement is only performed if the valve cannot be repaired6 7. In many cases 
the patients would not survive the additional constraint of mitral valve replacement. Mitral valve 
repair results in a smaller pressure gradient across the valve, compared to an artificial valve, and an 
intact unit of chordae and papillary muscles contributes significantly to systolic work. The most 
severe cases would in the end be candidates for heart transplantation. 
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There have been several studies on short-term follow-up of similar patient groups, but not many on 
long-term. In addition to this physical follow-up we wanted to study the life quality of the surviving 
patients.  
 
MATERIAL AND METHODS 
Patients 
This study was performed at the Sharee Zedek Medical Centre in Jerusalem, Israel, at the Cardiac 
Thoracic Surgery Department. We included all patients who underwent surgical mitral valve repair 
(MVr) for severe insufficiency due to ischemic cardiomyopathy, between 1996 and 2004. The 
follow-up was performed mainly between December 2004 and January 2005. The control group for 
SF-36 was the Urban Jewish Population between 45 and 75 years8. 
 
The preoperative patient data were retrieved from the hospital’s journal/database. The regular 
follow-up of the patients is done every second year. The patients are called up at home, and an 
assistant (mainly a medical student under special supervision) asks questions about the patient’s 
health and their complaints. Their NYHA functional class was derived from these data. If the last 
follow-up was more than 6 month ago, this was done by E.A or H.P.M during the investigation 
period. Some patients forwarded their files from other hospitals because of severe morbidity or 
difficulties with describing their medical condition. 
 
All survivors were invited to an echocardiographic examination and a quality-of-life assessment 
(SF-36 questionnaire). If a patient had a deterioration of their echo-results since last follow-up, they 
were offered an appointment with a cardiologist. Patients who had a long travel to the hospital or 
poor fitness, had their echo examination done at their local hospital, and answered the SF-36 
questionnaire at home. These patients received their questionnaire by mail or fax. 
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The short-form 36 (SF-36) 
The SF-36 is a multi-purpose short-form health survey with 36 questions. The questionnaire 
consists of eight scales, to measure health; physical functioning (PF), social functioning (SF), role 
limitation attributed to physical problems (RLP), role limitation attributed to emotional problems 
(RLE), mental health (MH), energy/vitality (E/V), bodily pain (BP) and general health perception 
(GH). The answers of the 36 questions are divided into these 8 categories and transformed to give 8 
scores between 0 and 100, with 0 being worst state, and 100 best. There are also two standardised 
summary scores that can be calculated from the SF-36; the physical component summary (PCS) and 
the mental health component summary (MCS). From the Israeli Ministry of Health we received the 
official translation of the SF-36 to Hebrew, which was used in the survey. The SF-36 values of the 
Urban Jewish Population between 45 and 75 years were used for comparison8.  
 
For the Hebrew and English-speaking patients the SF-36 was provided in their own language. The 
Arabic- and Russian-speaking patients brought with them a translator, usually a younger family 
member. The patients, who answered the SF-36 at the hospital, usually had an accompanying 
family member who could explain the questions when necessary. The questionnaires were analysed 
according to the “SF-36 Health Survey- Manual and Interpretation Guide”9. 
 
Echocardiography 
The patients had a general echocardiographic examination performed by the technicians at the 
cardio lab. A cardiologist always reviews the taped video recording and corrects the results when 
necessary. We registered the ejection fraction (EF %) and the LVEDD (Left Ventricular End 
Diastolic Diameter). Preoperative measurements were retrieved from the hospital’s database. 
 
Survival data 
Most of the mortality data were available in the hospital files/database. 
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Statistics  
We analyzed the SF-36, the preoperative data and the follow-up data with SPSS or Excel data sheet. 
Student’s t-test was used for comparison between groups. Survival data was analysed with the 
Kaplan-Meyer scale. The risk factors, immediate post-operative complications and the preoperative 
NYHA-class were analyzed with the Chi-square test. Because the low number of patients we used 
the continuity correction with 2-sided asymptomatic significance evaluation. For the analysis of 





The study consisted of 41 patients with severely compromised left ventricular function of ischemic 
aetiology, in which mitral valvuloplasty was performed. 88% were in NYHA functional-class III or 
IV at the time of surgery. 76% were men and 24% women, and their average age was 61.9 years. 38 
patients had documented myocardial infarcts and in the remaining three, coronary angiography 
demonstrated a vascular cause of cardiomyopathy. 76 % had a mitral insufficiency of grade 4, 22 % 
had grade 3 and 2 % grade 2. Table 1 describes baseline data of the patients.  
 
Table 1. Baseline data of the patients. 
Category All patients (n=41) 
Female 24 % (n=10)
Male 76 % (n=31)
Age 61,9 (Range 45-82)
NYHA-class 3,65 (Range 1-4)
LVEDD (cm) 6,06 (Range 5,3-6,7)
  
NYHA - New York Heart Association functional class 
 LVEDD – Left Ventricular End Diastolic Diameter 
  
The patients` main outcome are shown in Figure 1. 
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3 early/late  13 follow-up  25 patients 
deaths Survivors  op. deaths 
 
24 patients with follow-up 1 lost to follow-up 
 
1 patient no SF-36 
  
 
23 patients SF-36  
 and Echo results 
The category of operation of the patients is shown in Table 2a. 
Table 2a.  
Operative status All patients Survivors Non-survivors 
Elective (32 patients) 78 % (n=32) 84 % (n=21) 69 % (n=11) 
Urgent (6 patients) 15 % (n=6) 8 % (n=2) 25 % (n=4) 
Emergency (3 patients) 7 % (n=3) 8 % (n=2) 6 % (n=1) 
 
All patients underwent mitral valve repair, and most of them also had additional coronary artery by-
pass grafting (CABG) (95%), some of the patients had an additional valve repair or replacement 
(n=11). Their distribution is shown in Table 2b. 
 
Table 2b.  
Operation category  
CABG + MVr 71 % (n=29)
CABG+MVr+Other 20 % (n=8)
CABG+AVR+MVr+Other 2 % (n=1)
CABG+AVR+MVr 2 % (n=1)
MVr 2 % (n=1)
MVr + Other 2 % (n=1)
 AVR- Aorta Valve Replacement 
Their atherosclerotic and surgical risk factors are shown in Table 2c. 
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Table 2c Risk factors 
RISK FACTORS Starting point-group Survivors  Non-survivors p-value 
Smoking 63 % 68 % 56 % 0,67 
Diabetes 44 % 40 % 50 % 0,76 
Hypertension 46 % 40 % 56 % 0,49 
Hypercholesterolemia 54 % 48 % 63 % 0,56 
Obesity 17 % 16 % 19 % 1,00 
Cerebral Vascular 
Event 7 % 8 % 6 % 1,00 
COPD 12 % 12 % 13 % 1,00 
PVD 17 % 20 % 13 % 0,84 
Pulmonary 
Hypertension 51 % 44 % 63 % 0,40 
Renal failure 27 % 16 % 44 % 0,05 
Endocarditis 2 % 4 % 0 % 1,00 
Myocardial Infarction 93 % 88 % 100 % 0,41 
Chronic Heart Failure 90 % 84 % 100 % 0,25 
Atrial Fibrillation 15 % 4 % 31 % 0,05 
 COPD – Chronic Obstructive Pulmonary Disease 
 PVD – Pulmonal Ventricular Disease 
Follow-up 
The follow-up time was from 34 to 90 months after surgery, in average 58 months. The follow-up 
was 96% complete: one patient refused to answer any questions due to bitterness towards the 
hospital because of blindness as a complication to the surgery. No patient in the study was lost to 
follow-up, although not all answered the questions. Both the SF-36 as well as the echo-follow-up-
results were available in 92 % of patients. 
 
Mortality 
Mortality was 39 % (16 of 41 patients). During our follow-up calls we discovered a few deaths in 
addition to those registered in the hospitals files. In-hospital mortality was 7% (3 patients) and 
follow-up mortality was 32% (13 patients), in average death occurred 17 months after the initial 
operation. In 69 % the cause of death was cardiac and in 15 % cerebrovascular. Survival is 
























Survival Function Kaplan-Meyer plot
 
Baseline differences are shown in table 2d. 
 
 
Table 2d. Baseline differences between survivors and non-survivors. 
Category All patients 
Non-survivors 





b.l. and f.u. 
Women 24 % 31 % 20 %     
Men 76 % 69 % 80 %     
Age Range (45-82) 62 65 60     
EF       31,9   












NYHA IV   100% (n=16) 64% (n=16)     
NYHA III     16% (n=4)     
NYHA II     8%(n=2)     
NYHA I     8% (n=2)     
  




Table 3. Immediate post-operative complications 
Complications All patients Survivors Non-survivors p-value
Atrial fibrillation 10 % (n=4) 12 % (n=3) 6 % (n=1) 0,95
Low cardiac output 56 % (n=23) 60 % (n=15) 50 % (n=8) 0,76
Sepsis 10 % (n=4) 4 % (n=1) 19 % (n=3) 0,31
Cerebral vascular incidence 10 % (n=4) 4 % (n=1) 19 % (n=3) 0,31
Perioperative myocardial infarction 5 % (n=2) 0 % (n=0) 13 % (n=2) 0,29
Renal failure 5 % (n=2) 0 % (n=0) 13 % (n=2) 0,29
 
Three of the patients were reoperated; in all cases mitral valve replacement was done. 
 
We wanted to see the change of the NYHA-class from pre-operative to follow-up time. See table 4.  





At follow up 
Survivors 
NYHA IV 64% (n=16) 8% (n=2)
NYHA III 16% (n=4) 36% (n=9)
NYHA II 8%(n=2) 24% (n=6)
NYHA I 8% (n=2) 28%(n=7)
  
In one of the survivors we lack preoperative and postoperative NYHA classification. 
 
SF-36 – Quality of life- assessment 
The SF-36 was answered 92% of the survivors (23 of 25 survivors). See Table 5 for results. 





Control CI MVr CI Control p-value 
Physical functioning 50,65 (0-95) 78,28  36,92-64,39 77,23-79,32 <0,000
Role-Physical 46,73 (0-100) 68,46 28,33-65,15 66,77-70,14 0,012
Bodily Pain 58,69 (0-100) 69,38 46,27-71,12 68,22-70,55 0,073
General Health 45,52 (7-92) 63,55 34,35-56,69 62,62-64,48 <0,000
Vitality 43,04 (5-80) 56,73 33,83-52,26 55,8-57,66 0,004
Social Functioning 57,60 (0-100) 80,21 41,6-73,62 79,14-81,28 <0,000
Role-Emotional 52,17 (0-100) 77,18 33,05-71,3 75,59-78,78 0,002
Mental Health 52,17 (32-92) 67,32 47,9-63,75 66,45-68,2 0,010
CI=Confidence interval 
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Quality of life is significantly worse in patients for all categories, except for bodily pain. Borderline 
significance is seen for physical role and mental health. See Figure 4 for box plot of the SF-36 
results. There is a large individual variation. This can be seen in the large range of the different 
parameters. 
 




























Boxplot of SF-36 results
 
 
We calculated the SF-scores to physical component summary (PCS) and mental component 
summary (MCS) and got PCS score of 38.44 (15-57) and MCS score of 41.45 (22-60). 
Physical role and the NYHA-class had a correlation coefficient (Pearson) of 0.37 (0.38 Spearman 
Correlation). The p-value was 0.82 (0.73 Spearman).  
Physical functioning and the NYHA-class had a correlation coefficient (Pearson) of 0.67 (0.72 
Spearman Correlation). p-<0.0001. See figure 5. 
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The main findings of the present study are 
1. We find a modest survival (61 % (25 of 41 patients)) in patients followed for up to 8 years 
after surgery.  
2. The deaths were restricted to the patients with preoperative NYHA class IV.  
3. The surviving patients had an acceptable quality of life at follow-up. Their NYHA-class and 
physical functioning scores correlated significantly. 
4. Preoperative renal failure and atrial fibrillation were risk factors that significantly predicted 
death. 
Survival 
The follow-up was done in average 58 months after operation. We see from the Kaplan-Meyer plot 
that the deaths all occurred within the first 3 years.  The patients who survive the 3 first years after 
surgery thus should be clinically stable with a good result of the treatment, and likely to survive for 
years. The preoperative NYHA-class for the survival-group was 3.4 preoperatively. The non-
survivors all had NYHA-class 4 preoperatively.  This was a significant difference with a p-value of 
0.02 and shows that the patients with NYHA-class IV have a more severe prognosis. When we 
looked at the risk factors as a predictor for survival, renal failure and atrial fibrillation showed 
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significant p-values. This may be used in the preoperative evaluation of the patients. In the analysis 
of immediate post-operative complications we did not find any factor that was significant. Low EF 
is also reported to be a predictor10, but in the present study we lack data on preoperative EF in 
many. In general, EF is useful for evaluation of chronic heart failure; however, the presence of 
mitral valve insufficiency reduces the value of EF to predict left ventricle contractility. An 
alternative measure is the LVEDD, and all patients had severe left ventricular dysfunction reflected 
by dilated left ventricular diameters preoperatively. The LVEDD did not change significantly.  
 
In the period 1993-99, 21 patients with severe MI and ischemic cardiomyopathy received mitral 
valve repair at the same Israeli hospital. The report on these patients shows an excellent 3-year 
survival of 86% (3/21 died)11. The difference in survival is difficult to explain. One possible 
explanation could be that in the first study the mean follow up was only 13 months, compared to 58 
months in our study. Although mitral valve surgery has been performed for many years, valve 
repair on patients with ischemic cardiomyopathy only started in the 90-ies12. The mortality of 63% 
after an average of 5.8 years is high, but not considering the gloomy prognosis of these patients had 
they not been operated upon. Although operation prolongs life-expectancy; it does not stop the 
progression of the heart disease. Bishay et al13 show a similar group with a 2- and 5- year survival 
of 86 and 67%, respectively Bolling14 showed 1- and 2- year survival of 80 and 70%. 
Lee et al15 showed that left ventricular dysfunction remains a major cause of mortality and 
morbidity following mitral valve repair. In contrast, renal failure on dialysis, stroke, no angina, age 
>65 yrs, absence of hypercholesterolemia, EF<26% but not 3/4+MR were independent predictors of 
“Initial late mortality”16. Working with almost the same material as our study is based on; 
Silberman et al showed that mitral valve repair offers a survival advantage as compared to 




Results of surgery in the survivor group 
In our study we did not see a significant change in the LVEDD from preoperatively to follow-up. 
This is consistent with other findings20, but there are also opposite results18. Despite this we see 
symptomatic improvements being reflected in the NYHA-class changes. The NYHA-class was 
average 2.2 at follow up. The average EF at follow-up was 31.9%. It gives us a picture of the 
surviving patients. Preoperatively they all had a dysfunctional myocardium. The contractility of 
myocard probably does not change so much after the operation, but because the repair of the mitral 
valve, the mitral insufficiency decreases, thus the efficiency increases.  
 
Quality of life - The SF-36 
The SF- 36 consists of an 8-scale profile of functional health and well-being scores as well as 
psychometrically-based physical and mental health summary measures and a preference-based 
health utility index. It is useful in a variety of clinical settings since the questions are not disease-
specific. The SF-36 showed one not significant difference compared to the standard group: bodily 
pain was the only level not significantly lower in our patient-group compared to the control-group. 
This fits with the assumption that chronic heart failure should not contribute to bodily pain. The 
reductions in physical role and mental health scores in the patients were modest (close to being 
statistically significant). 
The individual SF-36 results showed large variations. There were patients with all scores between 0 
and 35 and on the other hand several patients with scores between 50 and 100. This was related to 
their NYHA-class. But emotional role and social functioning scores were not at all related to the 
NYHA-class. This can reflect that a big part of quality of life is also dependent on the people 
surrounding the patients and their own attitude to life.  
 We compared the physical functioning score and the estimated NYHA-class and got a correlation 
coefficient of 0.67 (0.72 Spearman Correlation) with a significant p-value. This reflects that the 
NYHA-evaluation says something about the ability to perform physical activities and that the 
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physical functioning score can predict the NYHA-class. 
 
We compared the physical role with the estimated NYHA-class and we did not get a significant 
correlation. Although the best and the worst scores seem to show a correlation, those with NYHA-
classes of 2 and 3 had a large variation in their SF-score. This may be due to other factors of 
limitations, like rheumatologic diseases. 
 
In our study the group consists of very sick people. Without surgery they would not survive for 
long20. There has been a study showing that patients with impaired LV function and ischemic mitral 
insufficiency were unlikely to demonstrate a significant improvement in quality of life at 3 months 
follow up19. Despite this MVR can be performed with low perioperative morbidity and mortality 
even in patients with advanced heart failure20.   
 
Limitations 
o Lack of preoperative SF-36 results 
Our study was to a large extent limited to follow-up. We have several preoperative medical data of 
the patients, but lack the SF-36 results preoperatively. Despite this, we would presume that a 
preoperative SF-36 evaluation would show poor quality of life. Our data was compared to the 
Urban Jewish population between 45 and 758. In a lot of countries they have a national registry with 
the scores of the SF-36 among the general population at different ages. This does not exist in Israel, 
so our data are the closest we came to this kind of general information about the countries citizens. 
This is not optimal, but it says something about the difference between our group of relative sick 
people and the general population. The hospital is now starting to assess the SF-36- score of 
patients preoperatively, and in the future it will be possible to do another study with more complete 
data. There are few patients every year, and therefore the data of these is still not ready at the 
endpoint of this study. 
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o The way the questions were asked. 
The Israeli population is very mixed. The language background of the patients was Hebrew, 
English, Arabic and Russian. We had the translation of the questionnaire into English and Hebrew, 
but lacked the translations to Arabic and Russian. Although we may assume that the persons 
translating the questions to the patients were competent, there is a possibility of misunderstanding 
and misinterpretation. 
 
The patients who answered the SF-36 at the hospital, had someone familiar with the questionnaire 
was sitting beside them, explaining difficulties if necessary. This may be a different setting from the 
patients answering at home, who did not have this extra help. 
 
Due to the limited number of patients, we (also) had a statistical power problem with the 
comparisons. We have the preoperative-data, and risk-factors, but the SF-36 questionnaire was only 
initiated at the point of the late follow up of this patient group.  
 
Other limitations 
o Gathering of NYHA-data  
The NYHA-functional class of the patients were evaluated preoperatively and during follow up. It 
is based on several questions about the patient’s physical abilities. Although these questions are 
standardized, there will always be a component of subjectivity in the evaluation of the answers.   
 
Mortality was 39 % or 16 patients out of 41 at the time of our investigation. The prognosis of 
patients with chronic heart failure has changed very much the last 20 years. Some of the most 
important reasons for that is newer and better medical treatment on the one hand, and on the other 
hand improvement of surgical technique.  The reports on the prognosis of patients with NYHA-
functional class III and IV without surgery, data are from patients offered yesterday’s medical 
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treatment. Today, drug and device treatment for severe heart failure has improved considerably, and 
therefore we cannot be absolutely sure that the results are still valid. However, it is reasonable to 
assume that without surgical intervention the life expectancy of these patients are still very poor. 
 
Operation? 
Despite the lack of prospective, randomized studies on the topic, there is large evidence supporting 
the superiority of mitral valve repair over replacement6, 7, 21.  Lately a discussion about the method 
of treatment of this group of patients has started22.  
 
CONCLUSION 
The primary aim of mitral valve surgery and the medical care around it is to improve survival as 
well as the overall functional capacity and health of patients. Despite that in the survivors, the 
LVEDD did not change significantly; the NYHA-class did improve, and also the symptoms. Our 
results of quality of life may be useful during the assessment and counselling of patients 
preoperatively. The atrial fibrillation and renal failure as risk factor show a significant correlation to 
death as end-point and can be used as the preoperative evaluation of patients before elected for 
operation. Although mortality is high, the perioperative mortality is low and there are patients who 
are in good mental and physical state at long-time follow-up. This study does not provide much new 
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